Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia

Cirrhotic Ascites Clinical Trial

Official title:

A Randomized, Double Blind, Placebo Controlled, Phase II, Dose-titration Trial to Explore the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of M0002 in Cirrhotic Subjects With Ascites and Hypo- or Normonatraemia.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01179607
• Other study ID #: M0002-BEL-C201
• Status: Completed
• Phase: Phase 2
• First received: August 10, 2010
• Last updated: August 10, 2010
• Start date: June 2007
• Est. completion date: December 2007

Study information

• Verified date: July 2010
• Source: Movetis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health ProductsGermany: German Institute of Medical Documentation and Information
• Study type: Interventional

Clinical Trial Summary

M0002, an orally active, selective non-peptidergic antagonist of the vasopressin V2 receptor inhibits vasopressin-induced water reabsorption from the kidney. Therefore the aquaretic effect of M0002 has a potential clinical benefit in the treatment of ascites and hyponatreamia in cirrhotic patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: December 2007
• Est. primary completion date: December 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Main Inclusion Criteria:

1. Subjects with any form of cirrhosis with ascites and who had at least 1 paracentesis of at least 4 liter in the last 6 months.

2. Dose of diuretics of spironolactone and furosemide was to be stable for at least one week prior to the screening visit or subject was refractory to diuretics.

3. Subjects had to have been on a salt restricted diet (< 5.2 grams sodium/day, 90 mmol) during the screening period prior to the trial drug administration.

4. Other treatment for the management of cirrhosis and ascites should be stable for at least 2 weeks prior to trial drug administration.

5. Child-Pugh B and C liver cirrhosis score lower than 12.

6. Subjects with hyponatraemia with sodium level between 120 and 132 mmol/l or normonatraemia with sodium level between 133 and 145 mmol/l measured at screening visit and day 1.

Main Exclusion Criteria:

1. Women of child bearing potential (WOCBP)

2. Functional transjugular intrahepatic portasystemic stent shunt (TIPS), peritoneovenous shunt

3. Liver transplantation

4. Budd-Chiari syndrome

5. Unstable hepatic disease (acute hepatitis, AST or ALT > 5 x upper limit of normal, bilirubin > 10 mg/dL)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Ascites
• Cirrhotic Ascites

Intervention

Drug:
• M0002

• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Movetis

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma sodium levels, weight, number of paracentesis		15 days	No